Role of substance P in hydrogen sulfide-induced pulmonary inflammation in mice.
Madhav Bhatia, Liang Zhi, Huili Zhang, Siaw-Wei Ng, Philip K Moore
Index: Am. J. Physiol. Lung Cell. Mol. Physiol. 291(5) , L896-904, (2006)
Full Text: HTML
Abstract
We have shown earlier that H(2)S acts as a mediator of inflammation. In this study, we have investigated the involvement of substance P and neurogenic inflammation in H(2)S-induced lung inflammation. Intraperitoneal administration of NaHS (1-10 mg/kg), an H(2)S donor, to mice caused a significant increase in circulating levels of substance P in a dose-dependent manner. H(2)S alone could also cause lung inflammation, as evidenced by a significant increase in lung myeloperoxidase activity and histological evidence of lung injury. The maximum effect of H(2)S on substance P levels and on lung inflammation was observed 1 h after NaHS administration. At this time, a significant increase in lung levels of TNF-alpha and IL-1beta was also observed. In substance P-deficient mice, the preprotachykinin-A knockout mice, H(2)S did not cause any lung inflammation. Furthermore, pretreatment of mice with CP-96345 (2.5 mg/kg ip), an antagonist of the neurokinin-1 (NK(1)) receptor, protected mice against lung inflammation caused by H(2)S. However, treatment with antagonists of NK(2), NK(3), and CGRP receptors did not have any effect on H(2)S-induced lung inflammation. Depleting neuropeptide from sensory neurons by capsaicin (50 mg/kg sc) significantly reduced the lung inflammation caused by H(2)S. In addition, pretreatment of mice with capsazepine (15 mg/kg sc), an antagonist of the transient receptor potential vanilloid-1, protected mice against H(2)S-induced lung inflammation. These results demonstrate a key role of substance P and neurogenic inflammation in H(2)S-induced lung injury in mice.
Related Compounds
Related Articles:
2015-02-01
[Br. J. Pharmacol. 172(3) , 924-39, (2015)]
2008-05-01
[Am. J. Physiol. Lung Cell. Mol. Physiol. 294(5) , L912-20, (2008)]
2006-11-01
[Am. J. Pathol. 169(5) , 1663-70, (2006)]
2006-10-01
[J. Neuroimmunol. 179(1-2) , 1-8, (2006)]
2008-10-10
[Neurosci. Lett. 443(3) , 257-60, (2008)]